Resonant Clinical Solutions Expands Global Footprint with Labfish Acquisition

Resonant Clinical Solutions, a prominent global partner in clinical solutions, has made a significant stride in its expansion by acquiring Labfish Rental Solutions GmbH, a specialized company based in Germany. This strategic acquisition not only augments Resonant's operations but also places it at the forefront of the clinical trial equipment and ancillary market in Europe.

The Impact of the Acquisition

On October 3, 2026, the announcement was made, revealing that Labfish and its subsidiaries in the United States and the United Kingdom provide comprehensive rental and calibration solutions for clinical and laboratory equipment. This move is anticipated to broaden Resonant's presence across Europe and bolster its capabilities in supporting increasingly complex clinical trial programs worldwide. With the central operations located in Hamburg, Labfish has become a key player known for its extensive inventory of laboratory equipment available for rent, including scales, freezers, refrigerators, infusion pumps, and monitors, alongside offering industry-leading calibration expertise.

Enhancing Clinical Trial Support

The acquisition is particularly timely as the demands of clinical trials evolve, necessitating specialized equipment and logistical support that aligns with changing research protocols and workflows. By integrating Labfish into Resonant's Auxiliary Equipment division, the company can now offer its clients a robust suite of services tailored to their unique needs, significantly enhancing the technical expertise available in Europe as their development programs expand.

Christophe Berthoux, CEO of Resonant Clinical Solutions, emphasized the value of this acquisition, stating, “Integrating Labfish into our Auxiliary Equipment division not only enhances our footprint in Europe but also strengthens our calibration and import/export services, further empowering the premier clinical trial solutions that our clients depend on.”

A Partnership Built on Expertise

The founder of Labfish, Martin Forster, expressed enthusiasm about joining forces with Resonant, highlighting the potential to expand Labfish's calibration services and logistics. Forster noted that their extensive experience in calibration, coupled with Resonant's capabilities, positions them to provide unparalleled support throughout various stages of clinical trial processes.

Labfish's Proven Track Record

Founded in 2014, Labfish operates one of Europe’s largest calibration facilities and is ISO 9001 certified, ensuring its services meet the highest standards in quality and reliability. The company is well-regarded for its IOR/EOR (Importer of Record/Exporter of Record) services and direct patient logistics management, collaborating with associated warehouses in countries such as Argentina, Israel, Turkey, and China. Their involvement has reached over 70 countries, further asserting their international presence.

The Future of Clinical Solutions

As clinical trials become more intricate, the demand for reliable and efficient equipment, calibration, and logistical support continues to grow. The addition of Labfish aligns perfectly with Resonant's mission to provide end-to-end solutions that simplify complexities in the clinical supply chain and sample lifecycle management. With a workforce exceeding 850 employees across the U.S., the U.K., and Europe, Resonant manages over 100 million research assets and has supported thousands of clinical trials.

As the company moves forward, this strategic acquisition is set to enhance Resonant’s offerings and provide invaluable support to pharmaceutical, biotechnology, and diagnostics companies engaged in clinical research. Resonant is committed to empowering its partners through comprehensive global solutions, enabling them to focus on what truly matters: science and patient care.

For more information, visit resonantclinical.com.